Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / RAD - Radiopharm Theranostics secures pivotal isotope for cancer-targeting peptide

RAD - Radiopharm Theranostics secures pivotal isotope for cancer-targeting peptide

Rite Aid Corporation

(NewsDirect)

RadiopharmTheranostics Ltd (ASX:RAD) CEO Riccardo Canevari chats with Proactiveafter the company signed a milestone supply agreement for an isotopeused in cancer therapy. The agreement will support the company’s RAD602 asset, a potential first-in-class radiopharmaceutical for treatingbrain cancers. Canevari says the isotope could expand treatmentoptions for patients living with cancer while giving Radiopharm acompetitive advantage as it embarks on a Phase 1 clinicaltrial.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information
Company Name: Rite Aid Corporation
Stock Symbol: RAD
Market: NYSE
Website: riteaid.com
Menu
RAD RAD Quote RAD Short RAD News RAD Articles RAD Message Board
Get RAD Alerts

News, Short Squeeze, Breakout and More Instantly...